Evropska unija - slovenščina - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - velagluceraza alfa - gaucher bolezen - drugi zdravljene bolezni prebavil in presnove izdelki, - vpriv je indiciran za dolgoročno encimsko nadomestno zdravljenje (ert) pri bolnikih z gaucherjevo boleznijo tipa 1.

Evropska unija - slovenščina - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - acromegaly - hipofize in hipotalamični hormoni in analogi - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Evropska unija - slovenščina - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Evropska unija - slovenščina - EMA (European Medicines Agency)

amryt pharmaceuticals dac - metreleptin - lipodystrophy, družinsko delno - drugi zdravljene bolezni prebavil in presnove izdelki, - myalepta je indicirano kot dodatek k dieti kot nadomestno zdravljenje za zdravljenje zapletov leptin pomanjkljivost v lipodystrophy (ld) bolnikov:s potrjeno prirojene splošnih ld (berardinelli-seip sindrom) ali pridobljenih splošnih ld (lawrence sindrom) pri odraslih in otrok do 2 let starosti in abovewith potrdili družinsko delno ld ali pridobljeno delno ld (barraquer-simons sindrom), pri odraslih in otrok 12 let in zgoraj za katere standardno zdravljenje ni uspelo doseči ustrezno presnovno nadzor.

Evropska unija - slovenščina - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - immunostimulants, - besremi je označen kot monotherapy pri odraslih za zdravljenje polycythaemia vera brez simptomatsko splenomegaly.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imunski sera in imunoglobulini, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

intas pharmaceuticals limited - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

intas pharmaceuticals limited - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

intas pharmaceuticals limited - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan